SC Filed 2020-06-01 Event — SEC 0001140361-20-012844 →

KKR Genetic Disorder L.P. → BridgeBio Pharma, Inc. BBIO

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

10 13D/G filings on this issuer

9 other filings besides this one

Filer Track Record

3 filings by this filer

2 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 5.38

25,750,649 shares short · +6.8% vs prior

Institutional Consensus · 2026-03-31

Held by elite portfolio managers

2 holders · $880.00M

Point72 Asset MgmtViking Global

Other 13D/G Filings on BridgeBio Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-10	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	5.00%	9,792,219	view →
2026-05-29	SCHEDULE 13G	Farallon Capital Partners, L.P.	—	—	view →
2026-04-02	SCHEDULE 13D/A	VIKING GLOBAL INVESTORS LP	6.10%	11,842,434	view →
2025-07-01	SCHEDULE	VIKING GLOBAL INVESTORS LP	9.80%	18,602,920	view →
2025-05-14	SCHEDULE	KKR Genetic Disorder L.P.	7.00%	13,260,971	view →
2025-03-07	SCHEDULE	KKR Genetic Disorder L.P.	10.10%	19,260,971	view →
2025-01-31	SCHEDULE	VIKING GLOBAL INVESTORS LP	11.70%	22,055,375	view →
2023-07-20	SC	VIKING GLOBAL INVESTORS LP	—	—	view →
2021-01-26	SC	Eidos Therapeutics, Inc.	—	—	view →

Other Filings by KKR Genetic Disorder L.P.

Filed	Form	Issuer	Stake	Shares
2025-05-14	SCHEDULE	BridgeBio Pharma, Inc. BBIO	7.00%	13,260,971	view →
2025-03-07	SCHEDULE	BridgeBio Pharma, Inc. BBIO	10.10%	19,260,971	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →